Bavarian Nordic secures $157 million contract for smallpox vaccine

U.S. government aims to replenish inventory

Danish company to manufacture more Jynneos vaccine

Bavarian Nordic has secured a $157 million contract from the U.S. government to manufacture more of its smallpox vaccine, Jynneos.

The contract will help replenish the U.S. government's inventory of bulk vaccine, which is required for future manufacturing and supply of freeze-dried vaccines.

The U.S. Biomedical Advanced Research and Development Authority (BARDA) requested the additional vaccine as concerns grow over the spread of monkeypox.

Monkeypox is a rare but potentially serious disease that is caused by a virus. Symptoms of monkeypox include fever, headache, muscle aches, and a rash.

There is no specific treatment for monkeypox, but the vaccine can help to prevent the disease.

Bavarian Nordic's Jynneos vaccine is the only FDA-approved vaccine for monkeypox.